The scientific and commercial members of the globally unique radiopharmaceutical competence cluster Dresden/Radeberg (Saxony, Germany), comprehensively covering the entire radiopharmaceutical value creation chain from targetry, discovery over R & D, manufacturing, regulatory approval up to commercialisation have now formally launched a dedicated radiopharmaceutical innovation cluster under the brand name nukliD®.
NukliD® has gained official support and recognition as key future industry in Saxony! 🎉
In the presence of Saxony’s Prime Minister Michael Kretschmer and many important political representatives, the eight funding organisations, including ABX-CRO and ABX advanced biochemical compounds signed a memorandum that marks the beginning of this exciting collaboration in Dresden/Radeberg.
Being part of this dynamic cluster opens up new opportunities for collaboration, innovation, and global growth – for the region, our customers, patients in need, and our investors. We’re looking forward to jointly implementing visionary solutions advancing the field and contributing to further shaping the future of radiopharmacy.
The scientific and commercial members of the globally unique radiopharmaceutical competence cluster Dresden/Radeberg (Saxony, Germany), comprehensively covering the entire radiopharmaceutical value creation chain from targetry, discovery over R & D, manufacturing, regulatory approval up to commercialisation have now formally launched a dedicated radiopharmaceutical innovation cluster under the brand name nukliD®.
NukliD® has gained official support and recognition as key future industry in Saxony! 🎉
In the presence of Saxony’s Prime Minister Michael Kretschmer and many important political representatives, the eight funding organisations, including ABX-CRO and ABX advanced biochemical compounds signed a memorandum that marks the beginning of this exciting collaboration in Dresden/Radeberg.
Being part of this dynamic cluster opens up new opportunities for collaboration, innovation, and global growth – for the region, our customers, patients in need, and our investors. We’re looking forward to jointly implementing visionary solutions advancing the field and contributing to further shaping the future of radiopharmacy.
Find the full press release here.
Credits Photo: Jürgen Lösel